Repatha: Clinical benefit yes, cost benefit no
Senior Science Editor
Amgen Inc. presented detailed data for the FOURIER cardiovascular outcomes trial of its Repatha (evolocumab) at the American College of Cardiology (ACC) annual meeting, which showed that those benefits were clinically significant, not just statistically significant. But the magnitude of the effects reported also showed that for it to be cost-effective, Repatha's price will need to be significantly lower than its current list price of roughly $14,500 per year.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST